Hospira Issues Voluntary Recall Due to Iron Oxide Particulate in Vials - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Hospira Issues Voluntary Recall Due to Iron Oxide Particulate in Vials

Hospira, Inc., announced a voluntary recall of one lot of single-dose vials of Lidocaine HCI Injection, due to a customer complaint of discolored product with visible particles, identified as iron oxide, in the solution. Particulate also was embedded in the molded glass container, according to the recall announcement from Hospira.

The company has attributed the embedded particulate to supplier’s glass defect and is working with its supplier on implementing corrective and preventive actions.

The recall, which is to the user level, is for Lidocaine HCI Injection, USP, 2%, 20 mg per mL, 5 mL single-Dose Vial, Preservative-Free (NDC 0409-2066-05; Lot 25-550-DD, Expiry 1JAN2015). The product was packaged 10 units per carton/180 units per case in single-dose glass fliptop vials and was distributed nationwide to distributors/wholesalers, hospitals, and clinics from June 2013 through July 2013.   

Risk factors associated with the particulate include the potential for particulate to be injected and/or a delay in therapy. Hospira reports that it has not received reports of any adverse events associated with this issue for this lot.

Source: FDA and Hospira


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications

Click here